


BIOSYMPOSIUM

INNOVATING ANTIBODY DRUG CONJUGATES:

From mechanisms to market



WEDNESDAY 9 OCTOBER 2024

9:00 am – 5:00 pm AEDT | followed by networking

Format: In person

Ian Wark Theatre, CSIRO,
Research Way, Clayton VIC 3168

PREMIER SPONSOR



MAJOR SPONSORS



SUPPORTING SPONSORS



WELCOME

Welcome to our full-day BioSymposium

– ***Innovating antibody drug conjugates: From mechanisms to market.***

Antibody drug conjugates (ADCs) are one of the most promising developments in cancer treatment, and hold great potential to treat other diseases too.

This conference is dedicated to exploring the vast ADC landscape; topics will traverse mechanisms, R&D, cancer treatments and other applications, manufacturing, market dynamics, patent strategies, financial and commercial considerations, and policies to accelerate innovation in this space and improve health outcomes.

Joining you in the room are professionals from across the industry, including researchers, manufacturers, government representatives, and service providers; this is a unique opportunity to strengthen your network by connecting with key players who are contributing to the growth and success of ADCs. We encourage you to take full advantage of the day: ask questions, share insights, and, most importantly, forge new connections that will help shape the future of this space.

This event is co-developed with BioMelbourne Network members and other key industry stakeholders who provide valuable insights to support the strengthening and growth of the industry. A special thanks to our members and sponsors who make events such as this possible, and our guest speakers who generously share their time, knowledge and expertise.

I hope you feel inspired by the knowledge shared, and that you walk away with new ideas, stronger networks, and a renewed drive as you contribute to improving health outcomes through innovation.



Karen Parr,
CEO, BioMelbourne Network

PROGRAM

ACKNOWLEDGMENT OF COUNTRY

BioMelbourne Network respectfully acknowledges the Traditional Custodians of the unceded lands and waters of Victoria: the Bunurong, Gunaikurnai and Wurundjeri peoples, on which the BioMelbourne Network and our Victorian members work, and as well as the lands and waters of our members further afield. We pay respect to their Elders past and present. As Australia's first scientists, we acknowledge the significant contribution that they and other Aboriginal and Torres Strait Islander people have made and continue to make to the research and knowledge systems that inform our community and our sector.

We acknowledge that Aboriginal and Torres Strait Islander people continue to live in a spiritual and sacred relationship with this country and recognise our responsibility to continue to work towards reconciliation.

WELCOME AND OPENING SPEECH | 9:00 am




Karen Parr
CEO, Biomelbourne Network



Shelley Jackson
Director, Australian Medtech Manufacturing
Centre and Health Technologies,
Department of Jobs, Skills,
Industry and Regions,
State Government of Victoria



Marcus Zipper
Manufacturing Research Unit
Director, CSIRO Manufacturing



SESSION ONE | 9:15 am

UNDERSTANDING ADCS – THE FUNDAMENTALS AND EMERGING INNOVATIONS

The opening session will address the ADC landscape, exploring historical development, mechanisms, and emerging medical applications. Hear how Victorian innovators are progressing ADC R&D and overcoming local and global commercialisation barriers.

Followed by morning break

Session one chair



Brittany Ashton

Senior Associate,
FB Rice

Speakers



Prof. Christoph Hagemeyer

Director,
Monash Biomedical Imaging



Dr Michael Wheatcroft

Chief Scientist,
Telix Pharmaceuticals



Dr Charlotte Williams

Principal Research Scientist
Group Leader, Chemical Biology,
Diagnostics and Devices,
CSIRO Manufacturing

(Correct as of 26/9/24)

SESSION TWO | 11:05 am

ADC ADOPTION – TARGETING CANCER

Speakers will explore the impactful role of ADCs to treat HER2-positive metastatic breast cancer, lymphoma and other malignancies. Utilising case studies, discover the clinical significance of the advancements which are shaping the future of cancer health care.

Followed by lunch break

Session two chair



Dr Jason Lickliter

Chief Medical Officer,
Nucleus Network Pty Ltd

Speakers



Matthew Britland

Managing and Medical Director,
Medwise Consulting



Bryce Davies

Head of APAC Strategy,
Early Phase Oncology and
Innovative Therapies,
IQVIA



Dr Peter Savas

Medical Oncologist,
Peter MacCallum Cancer Centre

SESSION THREE | 1:25 pm

EMPOWERING FUTURE INNOVATION – POLICY, TRAINING AND OTHER ENABLERS

This session will address how to achieve long-term R&D, GMP manufacturing and innovation success in the ADC field through workforce training, strategy setting and policy changes. Explore the importance of connecting data, technology and analytics to optimise clinical trials, and understand how we prepare the next generation of scientists and professionals in this cutting-edge field.

Followed by afternoon break

Session three chair



Jo Sherriff

Engineering Compliance Manager
Senior Consultant,
SeerPharma Pty Ltd

Speakers



Patrick James

Group Leader,
Regulated Biomanufacturing,
CSIRO Manufacturing



Sarah Parsons

Regional Strategy
Execution Manager –
Novel Modalities and
Investment Projects,
Merck



Dr Anubhav Srivastava

Senior Program Manager,
IDT Australia



Dr Daniel Yuen

Postdoctoral Researcher,
Drug Delivery,
Disposition and Dynamics,
Monash Institute of Pharmaceutical
Sciences

SESSION FOUR | 3:30 pm

EXPANDING HORIZONS – MARKETS, FUNDING AND THE FUTURE

Showcasing expanding applications of ADCs beyond cancer treatment, gain insights about next-gen ADC drug development and the pipeline for cancer antibodies, regulation and safety. Our speakers will also discuss funding opportunities, market dynamics and commercialisation lessons from global leaders, as well as building commercial advantage through strong patent strategies.

Followed by networking

Session four chair



Prof. Susie Nilsson

Research Director,
Biomedical Manufacturing,
CSIRO Manufacturing

Speakers



Prue Cowin

Partner,
FB Rice



Charley Lu

Managing Director,
Panlabs Biologics
Senior Advisor,
Trican Biotechnology
Venture Partner,
Perseverance Capital



Paul McDonald

CEO,
IDT Australia



Jonathan Tobin

Partner,
Brandon Capital



Michael Bettess

Senior Investment Manager,
Brandon Capital

HOST

BioMelbourne Network



Web www.biomelbourne.org
Email info@biomelbourne.org
Phone +61 3 9063 4757
LinkedIn www.linkedin.com/company/biomelbourne-network/

About us

BioMelbourne Network is the peak body in the Victorian healthtech industry, driving engagement and growth through local and international networks. Since 2001, we have been actively fostering and growing an innovative, globally competitive sector and transforming our Network as well as the broader Victorian ecosystem.

Our members are diverse and experts in their respective fields, from early-career researchers to company executives and experienced directors, and start-ups through to large multinational corporations. We represent universities, researchers, manufacturers, government departments and the services sector, which includes commercialisation, product design and development, intellectual property, investment and legal sectors.

We are committed to maximising our value to the ecosystem through the delivery of our strategic plan.

PREMIER SPONSOR

State Government of Victoria



Web djsir.vic.gov.au/health-tech
Email medtech.pharma@ecodev.vic.gov.au

About us

Victoria is home to world-class health technology companies and is a preferred location for many global leaders including CSL, Moderna, BioNTech, Illumina, Telix Pharmaceuticals and Pfizer. International companies partner with Victoria for its outstanding strengths in commercial product development, its cost-competitive environment for basic discovery, clinical and commercial research, and its strong collaborative networks and supportive government.

Victoria is a global leader in health technologies research and manufacturing, delivering a sector value add of \$5.5 billion in 2022. Victoria's research and development capabilities include: infectious disease and diagnostics; digital health and patient monitoring; cancer; cell therapies and regenerative medicine; neuroscience; paediatrics.

Victoria's health technologies ecosystem is supported by its skilled and multicultural talent pool, favourable regulatory and research and development environment, and world leading infrastructure – all backed by the Victorian Government's long-term investment into the sector.

The Victorian Government has recognised health technologies as a priority industry sector for more than two decades and is committed to working with business to grow the research and innovation ecosystem. The Victorian Government has a global network of 23 international business offices, actively working with companies worldwide to assist them to partner with Victoria to develop novel health technologies and services.

We look forward to connecting with you.

For more information on how the Victorian Government can support your business, please visit our website.

MAJOR SPONSOR

CSIRO



Web www.csiro.au

Phone 1300 363 400

About us

CSIRO's vision is to create a better future for Australia by solving the greatest challenges through innovative science and technology.

We work with biomedical companies to deliver new medical treatments and technologies that benefit millions of people in Australia and overseas, helping them live longer, healthier and more productive lives.

CSIRO is one of the largest multidisciplinary science organisations in the world. Our biomedical work supports local businesses and the broader research community across preclinical, manufacturing, devices and sensors, diagnostics and eHealth.

Want to know more about
CSIRO capabilities, expertise,
and facilities in life sciences?
Join our Wilam community
[CSIRO Biotech R&D and translation](#)



MAJOR SPONSOR

Moderna

moderna®



Web www.modernatx.com

Email modernatx.com.au

Phone 1800 344 018

About us

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company is developing a range of new medicines and vaccines.

Moderna's mRNA platform is enabling the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases.

With a unique culture and a global team driven by the Moderna values and mindsets to responsibly shape the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com.au

SUPPORTING SPONSOR

FB Rice

FB RICE



The IP
Navigators

Web www.fbrice.com.au
Email contact@fbrice.com.au
Phone +61 3 8618 4100

About us

Founded over 70 years ago, FB Rice has become Australia's most trusted intellectual property firm, with offices nationwide and a well-established presence in New Zealand and South-East Asia.

Today, we bring world-leading expertise across biotechnology, chemistry, computer and electrical sciences, engineering, and medical devices. With a focus on integrity and determination, we are committed to helping our clients achieve their goals. Our distinct advantage lies in our independent status—without external obligations, our sole focus is on the success of our clients. This dedication is reflected in our accolades, including 15 Australian Client Choice Awards and seven consecutive titles as Best Specialist IP Firm.

With decades of experience, we understand that the right advice can be the difference between success and frustration. Our diverse, multidisciplinary team consistently goes the extra mile to leverage IP for maximum commercial impact.

At FB Rice, we nurture and grow best-in-class attorneys who excel not only in intellectual property but also in understanding our clients' environments. We tailor IP advice and strategy to each client's unique needs, always striving to provide exceptional service. Our expertise, coupled with a commitment to making our clients feel comfortable and respected at every stage, sets us apart. We build partnerships based on trust by being open, approachable, and completely focused on our clients' needs.

At FB Rice, we champion innovation and create value.

SUPPORTING SPONSOR

Marsh



Web www.marsh.com/au/home.html
Email Louise.Clarke@marsh.com
Phone +61 409 617 945

About us

Marsh is the world's leading insurance broker and risk advisor. Thanks to its innovative, customer-led approach and deep sector experience, Marsh adds value to clients beyond just insurance, through comprehensive risk profile assessments and clear, easy-to-understand advice. Our comprehensive suite of services includes insurance coverage, risk assessment and mitigation strategies, claims management, and ongoing support to help you navigate the complex and ever-changing landscape of the life sciences industry.

Life sciences companies have the opportunity to truly change the world, but success depends on how well certain emerging and traditional risks are managed. Marsh's specialists can support your business objectives with risk strategies that promote resilience and competitiveness.

From program placement to claims management and risk consulting, we understand the bespoke challenges faced by your business and to your risks, whether you are in the pharmaceutical, biotechnology, medical device and supply, or contract research sector. As you manage complex regulatory requirements and unique market conditions, we will draw on our deep knowledge of your key risks to offer solutions that support your vision.

From a nimble start-up with a bold idea to a listed company bringing in revenue from overseas, success is dependent on knowing the right levers to pull and when. Marsh's dedicated life sciences team can help you navigate the relevant requirements and map out risk strategies and approaches — even as new issues emerge.

SUPPORTING SPONSOR

Radium Capital

R&DIUM CAPITAL

Contact Tim Hynes

Email tim.hynes@radiumcapital.com.au

Phone +61 3 9917 8968

About us

Radium Capital is Australia's market leader in Research and Development (R&D) financing. We believe businesses with R&D should have access to capital when they need it. So, we created Radium Advances to provide quick, easy and early access to up to 80% of expected R&D tax incentive refunds.

Radium Advances are available as a one-off cash injection, or can be used strategically multiple times throughout the year to smooth cash flow. The more you use Radium Advances the more your R&D benefits.

Under a quarterly model, for the same expenditure, you can:

- boost your R&D spend by 50% or reduce your outlay by 33%
- reinvest up to 150% of R&D expenditure back into R&D

We are passionate about supporting Australian innovators and since our inception in 2017, we have provided over \$750m of R&D funding to Australian innovation businesses.

Find out how innovators across Australia are using non-dilutive R&D financing to accelerate growth, attract other sources of funding and smooth cash flow at radiumcapital.com.au

SUPPORTING SPONSOR

SeerPharma Pty Ltd



Contact Biju Kishor
Web www.seerpharma.com
Email biju.kishor@seerpharma.com.au

About us

SeerPharma is a team of consultants that provide advice, training, software solutions from MasterControl, and contract labour resources to pharmaceutical, medical device and life science companies in the Asia-Pacific region, on matters of Quality Assurance and GMP compliance. We have been serving our clients in the Asia-Pacific region for over 30 years from our offices in Australia and Singapore, and are also able to provide assistance in Europe through our affiliate in the UK.

Our team of consultants have extensive experience working with clients supplying or looking to enter the supply chain of a therapeutic product. We work with organisations looking to ensure that their facilities, equipment, quality systems and processes are compliant with FDA, PIC/S, TGA, WHO, ISO, ICH and other GxP regulations and standards that apply to their product(s).

Through our work we aim to “Advance Quality and GMP Best Practices in the APAC region” for the Pharmaceutical and Medical Device Industry.



**Join
communities**



**Start
discussions**



**Download
resources**



**Searchable
directory**



**National event
calendar**



**Access the
BioResource Hub**

- 1.** Scan the QR code, click **Sign Up** & fill out registration form.
- 2.** Access Wilam via the link in the email sent to you.
- 3.** Click Log in, then **Can't Access My Account** & follow the prompts.
- 4.** Log in to Wilam & set up your profile.
- 5.** Join communities that interest you, explore the directory, promote your news, and view the national events calendar.





scan me

BioResource Hub

**BioMelbourne Network's hybrid events
in one place.**

Accessible anywhere, anytime.

Watch online now.



BioMelbourne Network membership

B E N E F I T S

BioMelbourne Network membership benefit is your introduction to the healthtech industry ecosystem here in Victoria.

In addition to supporting the sector, get access to:

NETWORKING AND CONNECTIONS

- Invitations to roundtable events and industry functions
- Key stakeholder and industry contacts
- Facilitated introductions as requested (in person or online).

PROMOTION

- New member introductions, news and job opportunities featured on our website, LinkedIn (14,000+ followers) and fortnightly newsletter, *In the Loop*
- Member profiles included in our online [member directory](#)
- Opportunities to share advice, knowledge and strategic insights with the network through contributions at events, on LinkedIn, Wilam and *In the Loop*.

EVENTS

- Discounted member registration to all BioMelbourne Network events (in person and online)
- Event hosting and sponsorship opportunities tailored to your interests and budget
- Opportunities to present at and contribute to our events, including input and planning
- Opportunities to participate in collaborative working groups and focus groups.



Join and engage with BioMelbourne Network

PREMIER SPONSOR



MAJOR SPONSORS



SUPPORTING SPONSORS

FB RICE



**BioMelbourne
Network**
Progressing BioIndustry



**BioResource
Hub**



BioMelbourne Network

Level 6, HWT Tower, 40 City Road, Southbank VIC 3006

T: +61 3 9063 4757 E: info@biomelbourne.org www.biomelbourne.org

#BIOSYM24